Stockreport

Magenta Therapeutics Presents Preclinical Data on MGTA-145, First-Line Stem Cell Mobilization Product Candidate for Autologous and Allogeneic Bone Marrow Transplant

Magenta Therapeutics, Inc.  (MGTA) 
Last magenta therapeutics, inc. earnings: 11/13 08:00 am Check Earnings Report
PDF -- A single dose of MGTA-145 plus plerixafor mobilized two to three times more stem cells in non-human primates than multi-day regimen of current standar [Read more]